US · Healthcare · Diagnostics & Research
EPS came in at 0.17 against a street estimate of 0.06 — a beat of 183.3%.
Analysts rate CareDx Inc a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $61.67.
CONFIDENT CareDx beat Q2 estimates, raised FY26 guidance to $495M revenue (+30% YoY) and $72M adjusted EBITDA. NavDX integration underway; ALAHEEM cell therapy trial data submitted; HistoMAP kidney launching 2027. CMS finalized Medicare coverage for transplant molecular testing. Q2 2026 Not geographically segmented in transcript; U.S.-focused. 110+ transplant centers contributed to ATC data; 56 centers in KOR kidney registry. Analysts pressed on CMS LCD field impact (none expected), specialty oncology growth conservatism (billing integration prudence), and NavDX ASP uplift timing (post-Q4 transition). Management balanced confidence with measured execution risk. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.31% |
| State Street Corp | 4.77% |
| Vanguard Capital Management, LLC | 4.25% |
| Deerfield Management Co | 3.86% |
| ARK Investment Management LLC | 3.78% |
| Boston Partners Global Investors, Inc | 3.75% |
| BAMCO Inc | 3.74% |
| Gagnon Securities LLC | 3.42% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CAREDX, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $373.6 million (June 30, 2026) vs. $65.4 million (Dec 31, 2025) — increase of | 2026-07-30 |
| Results announced · Q3 2026 CAREDX, INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Q2 2026 revenue: $132 million, up 52% year-over-year (vs. $87 million in Q2 2025) • | 2026-07-30 |
| Acquisition completed · Q2 2026 CAREDX, INC. – FORM 8-K SUMMARY (June 30 – July 1, 2026) --- HEADLINE NUMBERS • Eurobio Sale Completed (June 30, 2026): CareDx sold CareDx AB (Swed | 2026-07-07 |
| Board / officer change · Q2 2026 CAREDX, INC. – FORM 8-K SUMMARY (JUNE 11, 2026) HEADLINE NUMBERS • Annual Meeting held June 11, 2026 with 48,142,732 shares present (93% of outstand | 2026-06-15 |
| Quarterly report · Q1 2026 CAREDX, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total Revenue Q1 2026: $117.7 million vs. $84.7 million Q1 2025 (+38.9% year-over-year) | 2026-04-28 |
| Results announced · Q2 2026 CAREDX, INC. - Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue: $117.7 million (Q1 2026), up 39% year-over-year from $84.7 million (Q1 20 | 2026-04-28 |
| Proxy statement · Q2 2026 CAREDX, INC. 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION AND CHANGE • John W. Hanna (President and CEO) total compensation: Document references co | 2026-04-27 |
| Annual report FY2025 CAREDX, INC. - FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: CareDx, Inc. (NASDAQ: CDNA) – precision medicine company focused o | 2026-02-25 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of Naveris and sale of CareDx AB subsidiary CareDx completed two major transactions in late June/early July 2026. First, it sold its Swedish subsidiary CareDx AB and kitted laboratory products business to Eurobio Scientific for $171.7 | 2026-07-07 |
| Company enters into merger agreement and authorizes $100M stock repurchase program CareDx announced Q1 2026 financial results on April 28, 2026, along with two major corporate actions. First, the company entered into a merger agreement to acquire Naveris, Inc., though spec | 2026-04-28 |
| Entry into Purchase Agreement for transaction On April 15, 2026, CareDx, Inc. announced entry into a Purchase Agreement with Eurobio Scientific S.A. The company also disclosed preliminary unaudited financial results for Q1 2026 (quarter | 2026-04-16 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CareDx Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.